- 期刊
A Double-blind Experiment Comparing Loratadine and Astemizole for Perennial Allergic Rhinitis
Loratadine與Astemizole用於終年型過敏性鼻炎之雙盲試驗
摘要
為比較loratadine(10 mg，每天1次)和astemizole(10 mg，每天1次)之有效性、安全性及始作用時間，本雙盲、隨意交叉之研究收集了66名終年型過敏性鼻炎的病人，分成上述2個治療組外，還有1組是給予安慰劑，治療期間為14天。在第1,7及14天對其鼻症狀及非鼻部之過敏症狀，依其嚴重度的分數來加以評估。並給病人每日日誌自行記錄。在治療的頭7天特別是鼻部症狀，loratadine及astemizole治療群均有明顯改善。在14天治療完成後，astemizole及loratadine 2組在鼻部症狀，均獲顯著改善。但對非鼻部之症狀只有接受loratadine的治療群有明顯改善。和其他兩組比較，在loratadine(10 mg，每天1次)在有效性與安全性方面與astemizole並無顯著不同，但其較迅速的起始作用時間卻是有意義的差別。
關鍵字
無資料並列摘要
To compare the efficacy, safety and onset of action of loratadine (10 mg, one daily) and astemizole (10 mg, once daily), 66 patients with peren-nial allergic rhinitis were enrolled in the double – blind, randomized, parallel-gorup, placebo controlled study. They were treated for 14 days and evalu-ated at the first, 7th day and 14th day according to the nasal symptoms, non-nasal symptoms. These symptoms and therapeutic response were rated numerically daily on the diary cards by patients and the physician. During the first 7 days of treatment, patients of loratadine and astemizole groups experienced significant relief of their symptoms, especially nasal symptoms. After 14 days of treatment, we found that the total symptoms and individual nasal symptoms got very apparent improvement in loratadine and astemizole groups. For non-nasal symptoms, only the patients of loratadine group had very apparent improvement compared to the patients of astemizole and placebo groups. The onset of action in iloratadine group was significantly earlier than that in astemizole group. Adverse effects were minimal and no evident difference was noted among the three groups. In summary, lorata-dine has a significantly faster onset of action than astemizole with compara-ble safety and efficacy.